75%Confidence
0Views
FDASource
2026-03-24Date
Summary
Harvard Drug Group's packaging defect for Midodrine tablets reveals potential supply chain vulnerabilities in blister packaging operations that could compromise drug stability. This may affect patient access to this blood pressure medication and trigger additional packaging audits across their product lines.
Actionable: Monitor for potential supply disruptions in cardiovascular medications and verify packaging quality controls with suppliers.
AI Confidence: 75%
Data Points
firmThe Harvard Drug Group LLC
classificationClass II
statusOngoing
distributionNationwide US.
productMidodrine Hydrochloride Tablets, USP, 5 mg, 50 Tablets (5 x 10 blister packs), Rx only, Packaged and Distributed by: Major Pharmaceuticals, Indianapol
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now